Scarica l'app Stockscreener
17.18
1.00%
0.17
Dopo l'orario di chiusura:
17.18
Precedente Chiudi:
$17.01
Aprire:
$16.85
Volume 24 ore:
3.01M
Relative Volume:
1.62
Capitalizzazione di mercato:
$5.49B
Reddito:
$3.05B
Utile/perdita netta:
$181.32M
Rapporto P/E:
46.06
EPS:
0.373
Flusso di cassa netto:
$186.11M
1 W Prestazione:
+1.54%
1M Prestazione:
+6.05%
6M Prestazione:
+32.46%
1 anno Prestazione:
+106.24%
Intervallo 1D:
$16.82
$17.34
Intervallo di 1 settimana:
$16.45
$17.42
Portata 52W:
$7.665
$17.86
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
17.18 | 5.43B | 3.05B | 181.32M | 186.11M | 0.373 |
TAK
Takeda Pharmaceutical Co Adr
|
16.49 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.86 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.18 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.39 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
535.57 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-17 | Iniziato | UBS | Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Amneal Pharmaceuticals stock holds steady as generic pipeline supports long term growth - ad-hoc-news.de
Amneal schedules July 30 call for second-quarter 2026 results - Stock Titan
Amneal to Report Second Quarter 2026 Results on July 30, 2026 - The Manila Times
Amneals Planned Sterile Facility Creates Opportunity For Aseptic Filling Isolator And Automation Suppliers - Pharmaceutical Online
Enterprise value to revenue forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers - Yahoo Finance
Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Kiely John - Moomoo
Did EMA’s Positive Hopledo Ruling Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative? - Sahm
Amneal Sues Alembic to Block Copies of Crexont Parkinson’s Drug - Bloomberg Law News
Amneal Pharmaceuticals updates investors on its generics and specialty pipeline. The company focuses - ad-hoc-news.de
$2M from Amneal targets Parkinson's drug costs for patients - Stock Titan
Amneal Pharmaceuticals (AMRX) Gets EU Backing For Hopledo, Is It Fully Priced? - Sahm
Price to sales forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Amneal Pharmaceuticals : New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program - marketscreener.com
Price to book forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Price to earnings forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness - Sahm
Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters
Amneal to Buy Kashiv for $375M Cash + 28.9M Shares (NASDAQ: AMRX) - Stock Titan
EMA Recommends Approval of Hopledo for Parkinson's Disease - Intellectia AI
Zambon and Amneal Receive Positive CHMP Opinion for Hopledo in Parkinson’s Disease in Europe - Quiver Quantitative
EU regulator backs Amneal’s Parkinson’s drug after Phase 3 data - Stock Titan
Does Amneal (AMRX) Joining Three Russell 2000 Defensive Indexes Recast Its Risk Profile? - simplywall.st
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Value-Defensive Index - marketscreener.com
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Amneal Pharmaceuticals, Inc.(NasdaqGS: AMRX) added to Russell 2000 Defensive Index - marketscreener.com
Form DEF 14A Amneal Pharmaceuticals Inc Class A For: 26 June - Investing.com UK
2DT Forecast — Price Target — Prediction for 2027 - TradingView
Amneal Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:AMRX) - TradingView
AMRX Forecast — Price Target — Prediction for 2027 - TradingView
Amneal Pharmaceuticals (AMRX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX) - MSN
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD By Investing.com - Investing.com South Africa
Rytvela from Amneal Pharmaceuticals Inc.biosimilar for chronic uveitis care - AD HOC NEWS
Amgen Inc. v. Amneal Pharm. LLC United States Court of Appeals of the Federal Circuit, 2020 945 F.3d 1368, 2020 - Sage Journals
Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally - Sahm
Amneal (AMRX) agrees to buy Kashiv for $375M cash plus equity and milestones - Stock Titan
Amneal Pharmaceuticals Inc (AMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Institutional Confidence - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amneal Pharmaceuticals Inc - TradingKey
Amneal Pharmaceuticals, Inc. (AMRX) Latest Stock News & Headlines - Yahoo Finance
US progesterone supplies tighten as menopause treatment demand grows - Reuters
Amneal Pharmaceuticals Inc (AMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
Amneal Pharmaceuticals (AMRX) Is Up 17.8% After CREXONT Phase 4 Gains And New Oncology Launch - Yahoo Finance
Amneal Pharmaceuticals, Inc. (AMRX) hits fresh high: Is there still room to run? - MSN
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Do options traders know something about Amneal stock we don't? - MSN
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.13%
1.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):